Vemurafenib product-specific bioequivalence guidance

This document provides product-specific guidance on the demonstration of the bioequivalence of vemurafenib.

Keywords: Bioequivalence, generics, vemurafenib

Abbreviations:

• BCS Classification: Biopharmaceutics Classification System
• AUC_0-t: area under the plasma concentration curve from administration to last observed concentration at time t
• AUC_0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
• C_max: maximum plasma concentration

Current effective version

Vemurafenib film-coated tablets 240 mg product-specific bioequivalence guidance

AdoptedLegal effective date: 01/09/2017Reference Number: EMA/CHMP/476248/2016

Document history

Overview of comments received on 'Vemurafenib film-coated tablets 240 mg product-specific bioequivalence guidance’ (EMA/CHMP/476248/2016)

Legal effective date: 01/09/2017Reference Number: EMA/CHMP/803499/2016

Draft vemurafenib film-coated tablets 240 mg product-specific bioequivalence guidance

Consultation dates: 01/08/2016 to 31/10/2016Draft: consultation closedReference Number: EMA/CHMP/476248/2016Summary:

This document provides product-specific guidance on the demonstration of the bioequivalence of vemurafenib.